Medicxi Ventures Management’s Vaxcyte PCVX Stock Holding History

Medicxi Ventures Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,049,893	Closed	-$53.5M	–	6
2023 Q3	$53.5M	Sell	1,049,893 -265,542	-20%	-$13.1M	17.09%	2
2023 Q2	$65.7M	Sell	1,315,435 -141,865	-10%	-$6.72M	18.41%	2
2023 Q1	$54.6M	Hold	1,457,300	–	–	23.4%	2
2022 Q4	$69.9M	Sell	1,457,300 -430,178	-23%	-$16.9M	29.35%	1
2022 Q3	$45.3M	Hold	1,887,478	–	–	18.86%	3
2022 Q2	$41.1M	Hold	1,887,478	–	–	17.06%	3
2022 Q1	$45.6M	Hold	1,887,478	–	–	12.35%	3
2021 Q4	$44.9M	Hold	1,887,478	–	–	11.24%	4
2021 Q3	$47.9M	Hold	1,887,478	–	–	10.42%	3
2021 Q2	$42.5M	Hold	1,887,478	–	–	7.61%	3
2021 Q1	$37.3M	Hold	1,887,478	–	–	21.71%	2
2020 Q4	$50.1M	Hold	1,887,478	–	–	29.15%	2
2020 Q3	$93.2M	Hold	1,887,478	–	–	44.51%	1
2020 Q2	$59.7M	Buy	+1,887,478	New	+$60.7M	36.67%	2

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Medicxi Ventures Management's PCVX Position: Q4 2023 in Review

Medicxi Ventures Management sold out of Vaxcyte (PCVX) in Q4 2023, closing a stake of 1,049,893 shares — an estimated $53.5M sold.

Medicxi Ventures Management first reported a position in PCVX in Q2 2020 and held it in 14 quarters. The position peaked at $93.2M in Q3 2020. 223 funds tracked by Wall St. Rank hold PCVX as of Q4 2023.

Medicxi Ventures Management reported no remaining Vaxcyte position as of Q4 2023 after selling out during the quarter.
Medicxi Ventures Management sold 1,049,893 Vaxcyte shares in Q4 2023, an estimated $53.5M.
Medicxi Ventures Management first reported a position in Vaxcyte in Q2 2020 and held it in 14 quarters.
Medicxi Ventures Management's Vaxcyte position peaked at $93.2M in Q3 2020.
223 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2023.

Based on Medicxi Ventures Management's 13F filing for Q4 2023, filed 1 Feb 2024.